

Monika Gjorgjieva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1702801/publications.pdf>

Version: 2024-02-01

16
papers

941
citations

759055

12
h-index

996849

15
g-index

16
all docs

16
docs citations

16
times ranked

1116
citing authors

#	ARTICLE	IF	CITATIONS
1	Deciphering miRNAs' Action through miRNA Editing. International Journal of Molecular Sciences, 2019, 20, 6249.	1.8	518
2	miRNAs and NAFLD: from pathophysiology to therapy. Gut, 2019, 68, 2065-2079.	6.1	156
3	Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context. Molecular Metabolism, 2018, 16, 100-115.	3.0	46
4	Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia. Journal of Hepatology, 2018, 69, 1074-1087.	1.8	31
5	Rescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression. Molecular Therapy, 2018, 26, 890-901.	3.7	24
6	Inhibition of Glycogen Synthase II with RNAi Prevents Liver Injury in Mouse Models of Glycogen Storage Diseases. Molecular Therapy, 2018, 26, 1771-1782.	3.7	24
7	Genetic Ablation of MiR-22 Fosters Diet-Induced Obesity and NAFLD Development. Journal of Personalized Medicine, 2020, 10, 170.	1.1	21
8	Progressive development of renal cysts in glycogen storage disease type I. Human Molecular Genetics, 2016, 25, 3784-3797.	1.4	20
9	Hepatic stress associated with pathologies characterized by disturbed glucose production. Cell Stress, 2019, 3, 86-99.	1.4	20
10	mRNA Post-Transcriptional Regulation by AU-Rich Element-Binding Proteins in Liver Inflammation and Cancer. International Journal of Molecular Sciences, 2020, 21, 6648.	1.8	19
11	Mir-21 Suppression Promotes Mouse Hepatocarcinogenesis. Cancers, 2021, 13, 4983.	1.7	17
12	Polycystic kidney features of the renal pathology in glycogen storage disease type I: possible evolution to renal neoplasia. Journal of Inherited Metabolic Disease, 2018, 41, 955-963.	1.7	13
13	Mechanisms by Which Metabolic Reprogramming in GSD1 Liver Generates a Favorable Tumorigenic Environment. FIRE Forum for International Research in Education, 2016, 4, 232640981667942.	0.7	11
14	Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease. Molecular Therapy - Methods and Clinical Development, 2019, 15, 383-391.	1.8	10
15	Tristetraprolin Promotes Hepatic Inflammation and Tumor Initiation but Restrains Cancer Progression to Malignancy. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 597-621.	2.3	10
16	TIA1 Loss Exacerbates Fatty Liver Disease but Exerts a Dual Role in Hepatocarcinogenesis. Cancers, 2022, 14, 1704.	1.7	1